Bovine Plasma Market Size and Forecast — 2026-2033
Bovine Plasma Market is estimated to be valued at USD 1,019.3 Mn in 2026 and is expected to reach USD 1,532.6 Mn in 2033, exhibiting a compound annual growth rate (CAGR) of 6.0% from 2026 to 2033. It is prepared from the whole blood, which contains anticoagulant, cells, and other blood contents. Then it is centrifuged to remove cells and cellular debris. It contains 3.8% trisodium citrate as an anticoagulant. It undergoes clot testing, proving that the product's clotting factors are active. To determine whether any additional enzymes present are native or denatured, it is not examined. There are several type of bovine supplements used such as bovine colostrum used as a dietary supplement to improves human health and wellbeing and The antioxidant, antibacterial, and antiviral effects of bovine lactoferrin supplements are considered to increase the immune system and regulate immune cell activity.
Figure 1. Global Bovine Plasma Market Share (%), by Grade, 2026

Global Bovine Plasma Market– Drivers
Increasing number of product availability in the market is expected to drive the global bovine plasma market growth over the forecast period. For instance, on March 22, 2021, Thermo Fisher Scientific, a U.S.-based company that manufactures pharmaceutical and diagnostic products launched the new Gibco Human Plasma-like Medium (HPLM), which is the first cell culture medium in the market that mimics the metabolic profile of human plasma. Gibco HPLM has the same levels of over 60 polar metabolites including amino acids, nucleic acids, sugars, and tiny organic acids, as those found in human plasma.
The increase in the efforts by market players for smooth and consistent supply of key raw materials to ensure quality improvement is expected to boost growth of the global bovine plasma market over the forecast period. For instance, on December 01, 2021, Proliant Biologicals, which is a part of the Proliant group of companies that manufactures protein ingredients for food, health, nutrition and biologicals approved additional raw material suppliers for liquid plasma to manufacture the following stock keeping unit (SKU)’s at the Boone, artificial intelligence (AI) production facility. This agreement will be effective from June 1, 2022.
- Current Industry Events of 2026
- Market Size Estimation
- Regional Breakdown
- Competitive Landscape
- Customer Intelligence
- Segmental Analysis
- Pricing Analysis
- Key Market Drivers, Challenges & Future Trends
- Customized Insights Section
Bovine Plasma Market Report Coverage
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 1,019.3 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 6.0% | 2033 Value Projection: | USD 1,532.6 Mn |
| Geographies covered: |
| ||
| Segments covered: |
| ||
| Companies covered: | Thermo Fisher Scientific, Moregate BioTech, Gemini, Atlanta Biologicals, Tissue Culture Biologicals, Bovogen Biologicals Pty Ltd, Biowest, Internegocios S.A., ROCKY MOUNTAIN BIOLOGICALS, Sonac, Innovative Research, Lake Immunogenics., Canvax Reagents S.L., Merck KGaA, Cambridge Bioscience Limited, Bio-Techne, VWR International, LLC., Otto Chemie Pvt. Ltd., BioVision Inc, Pel-Freez, LLC, Canvax Reagents S.L., GeneTex, Inc, Cygnus Technologies, Equitech-Bio, and 3H Biomedical AB | ||
| Growth Drivers: |
| ||
| Restraints & Challenges: |
| ||
Figure 2. Global Bovine Plasma Market Share (%), by Region, 2026

The study examines bovine-derived immunoglobulin, which have been demonstrated in animal models to inhibit the development of more severe disease states, the advancement of infection-related inflammation, and post-COVID syndrome.
Global Bovine Plasma Market: Key Developments
On December 27, 2021, an article published in National Library of Medicine, it was found that after acidifying bovine plasma and adding nanofibrillated cellulose (NFC) for reinforcement, films made with ethanol-extracted proteins had greater properties than those seen in the untreated plasma control films. The mechanical and water vapour barrier qualities of these films, which were made with 10% NFC, significantly improved, and their water solubility decreased, without affecting their optical qualities such as light transmittance and transparency index. Additionally, it was discovered that antibacterial substances such as nisin can be easily incorporated into the formulation of these films.
Global Bovine Plasma Market: Restraint
High manufacturing cost of drugs developed from bovine plasma is expected to hinder growth of the global bovine plasma market. For instance, SAB Bio therapeutics, a biotech company, is focused on developing drugs by using genetically engineered cattle to produce large quantities of human antibodies-proteins that helps to remove harmful foreign pathogens from the body—in a rapid fashion that could be used to treat patients suffering from infectious diseases such as Middle East respiratory syndrome (MERS), Ebola, and influenza. The drugs manufactured using this technology could cost around US$ 2,000 per gram. Thus, high cost means that many countries that might benefit most from these drugs might not be able to afford manufacturing them on their own, which is expected to hinder the market growth.
Global Bovine Plasma Market- Key Players
Major players operating in the global bovine plasma market include Thermo Fisher Scientific, Moregate BioTech, Gemini, Atlanta Biologicals, Tissue Culture Biologicals, Bovogen Biologicals Pty Ltd, Biowest, Internegocios S.A., ROCKY MOUNTAIN BIOLOGICALS, Sonac, Innovative Research, Lake Immunogenics., Canvax Reagents S.L., Merck KGaA, Cambridge Bioscience Limited., Bio-Techne, VWR International, LLC., Otto Chemie Pvt. Ltd., BioVision Inc, Pel-Freez, LLC, Canvax Reagents S.L., GeneTex, Inc, Cygnus Technologies, Equitech-Bio, and 3H Biomedical AB
Sources
Primary Research Interviews
- Bovine plasma producers (e.g., APC Inc., Sonac (Darling Ingredients), Lauridsen Group, Proliant Biologicals)
- Animal feed, pet food and veterinary blood-product formulators
- Slaughterhouse by-product managers
Databases
- FAO livestock data
- USDA FSIS
- UN Comtrade blood plasma trade data
Magazines
- Feedstuffs
- Petfood Industry
Journals
- Animal Feed Science and Technology (Elsevier)
- Journal of Animal Science (ASAS)
Newspapers
- Reuters Agriculture
- Financial Times – Agriculture
Associations
- American Feed Industry Association (AFIA)
- International Feed Industry Federation (IFIF)
- EFPRA (European Fat Processors and Renderers Association)
Public Domain Sources
- U.S. FDA CVM animal feed
- EU animal by-products regulations
- ResearchGate publications on bovine plasma
Proprietary Elements
- CMI Data Analytics Tool, Proprietary CMI Existing Repository of information for last 10 years.
Get access to 250+ pages report
Every segment, forecast, competitor profile and data table behind the analysis above — available for instant download.
- ESOMAR Member
- ISO 9001:2015 Certified
- D-U-N-S Registered
- GDPR & CCPA Compliant
Missing comfort of reading report in your local language? Find your preferred language:
Transform your Strategy with Exclusive Trending Reports
Frequently Asked Questions
The Bovine Plasma Market is estimated to be valued at USD 1,019.3 Mn in 2026, and is expected to reach USD 1,532.6 Mn by 2033.
The CAGR of the Bovine Plasma Market is projected to be 6.0% from 2026 to 2033.
Factors such as increasing bovine product launch and approvals and increasing research and development activities are expected to drive the market.
Technical bovine is the leading grade segment in the market.
The major factors hampering growth of the market include high cost of bovine plasma derived product.
Major players operating in the market include Thermo Fisher Scientific, Moregate BioTech, Gemini, Atlanta Biologicals, Tissue Culture Biologicals, Bovogen Biologicals Pty Ltd, Biowest, Internegocios S.A., ROCKY MOUNTAIN BIOLOGICALS, Sonac, Innovative Research, Lake Immunogenics., Canvax Reagents S.L., Merck KGaA, Cambridge Bioscience Limited, Bio-Techne, VWR International, LLC., Otto Chemie Pvt. Ltd., BioVision Inc, Pel-Freez, LLC, Canvax Reagents S.L., GeneTex, Inc, Cygnus Technologies, Equitech-Bio, and 3H Biomedical AB.
